What the FDA labels say about taking them together
Aliskiren and perindopril
Perindopril's FDA label of March 13, 2024 names aliskiren in its contraindications section; aliskiren's label does not name perindopril itself but warns about its class (ACE inhibitors). The perindopril label: “Do not co-administer aliskiren with perindopril erbumine tablets in patients with diabetes. Perindopril erbumine tablets are contraindicated in combination with neprilysin inhibitor (e.g., sacubitril).”
Check it at the source: the aliskiren FDA label on DailyMed (effective March 7, 2024, LXO US Inc.); the perindopril FDA label on DailyMed (effective March 13, 2024, Aurobindo Pharma Limited).
What does the aliskiren label say about perindopril?
Aliskiren's label does not name perindopril itself; it warns about its class (ACE inhibitors):
Aliskiren label, warnings and precautionsIn general, avoid combined use of Tekturna with ACE inhibitors or ARBs, particularly in patients with creatinine clearance (CrCl) less than 60 mL/min [see Contraindications ( 4 ), Drug Interactions ( 7 ) and Clinical Studies ( 14.3 )].
Aliskiren label, drug interactionsIn general, avoid combined use of aliskiren with ACE inhibitors or ARBs, particularly in patients with CrCl less than 60 mL/min.
Source: FDA drug label (Tekturna), NDA021985 (Lxo Ireland), as published by LXO US Inc., effective March 7, 2024 (SPL set 3dd61fa5-1620-4ebf-bbdb-ede29b92fce2), via openFDA; the full label on DailyMed
What does the perindopril label say about aliskiren?
Perindopril label, contraindicationsDo not co-administer aliskiren with perindopril erbumine tablets in patients with diabetes. [see Drug Interactions (7.8) ] Perindopril erbumine tablets are contraindicated in combination with neprilysin inhibitor (e.g., sacubitril).
Perindopril label, drug interactionsBlockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
Source: FDA drug label (Perindopril Erbumine), Aurobindo Pharma Limited, effective March 13, 2024 (SPL set 87768fbf-7c63-47da-8925-0316f343d6ef), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aliskiren | Perindopril | |
|---|---|---|
| Labeled for | High blood pressure | High blood pressure, Heart attack and coronary artery disease |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $3.94 per tablet 150 mg tablet | $0.495 per tablet 4 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once